Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Tenax Therapeutics, Inc.NASDAQ: TENX
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments remains negative
Q1 FY2026 short-term investments was $0, compared with $0 a year earlier.
Context
- Short-term investments amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Short-term investments increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Investments vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's Mar 2026 short-term investments of $0 is the 5th highest of the 7 companies compared; the peer median is $53.58M.
- Short-term investments amounts to 0.0% of total assets for TENX, versus a peer median of 38.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $50.62B | — | — | 53.2% | |
| Jun 2026 | $94.37M | +4568.4% | — | 39.6% | |
| Mar 2026 | $75.36M | -38.8% | +17.2% | 53.5% | |
| Mar 2026 | $31.8M | -32.4% | -17.9% | 36.3% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding TENX) | $53.58M | -32.4% | -0.4% | 38.0% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.